Compare Ares Capital Corporation (ARCC) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs ARK Genomic Revolution ETF — how do they compare? Ares Capital Corporation trades at $19.96 (market cap $14.34B), while ARK Genomic Revolution ETF trades at $44.53. The key difference: Ares Capital Corporation pays a 9.61% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Ares Capital Corporation nearer its low. Which is the better fit depends on your goals.
| ARCC | ARKG | |
|---|---|---|
Market Cap | $14.34B | — |
Sector | Financials | Sector/Thematic |
52-Week High | $22.68 | $44.55 |
52-Week Low | $17.45 | $24.02 |
Dividend Yield | 9.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
